Atea Pharmaceuticals, Inc. (AVIR) — Institutional Holders & Catalysts | BiotechEdge

Catalysts Convergence Squeeze Signals Runway Insiders Research

Home›Companies›Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals, Inc.

AVIR

Held by 1 specialist biotech fund

High short interest · No specialist buying

1 fund opened new positions. Short interest: 12.8% of float.

Score Holdings Short Interest Catalysts Insiders Research

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Feedback Terms Privacy Disclaimer

Signal Score

1.5/10

1 fund opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Tang Capital ManagementNew

Short Interest

High short interest

Short Shares

7.99M

Change

+3.5%

Days to Cover

12.6

% of Float

12.8%

Settlement

Mar 13, 2026

Short interest over 2 periods

Catalysts

No catalysts tracked.

Activist Filings

SC 13G/AEcoR1 Capital4.0%Feb 14, 2025

SC 13G/AEcoR1 Capital6.4%Nov 14, 2024

SC 13G/AEcoR1 Capital8.4%Feb 14, 2024

SC 13G/AEcoR1 Capital7.4%Feb 10, 2023

SC 13G/ARA Capital Management0.0%Feb 14, 2022

SC 13GEcoR1 Capital6.5%Dec 10, 2021

SC 13G/ARA Capital Management6.5%Apr 7, 2021

SC 13GRA Capital Management6.5%Feb 16, 2021

Position Details

Tang Capital ManagementNEWFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

ABEO1 fund ACAD1 fund ACET1 fund ALT1 fund ANAB1 fund ANIP1 fund ARVN1 fund AUPH1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: